Phosphorex, LLC: Company Profile

Background

Overview

Phosphorex, LLC is a contract development and manufacturing organization (CDMO) specializing in particle-based drug delivery solutions. Established in 2005 and headquartered in Hopkinton, Massachusetts, the company has over two decades of experience in advancing nanomedicines from formulation to scale-up to clinical supply.

Mission and Vision

Phosphorex's mission is to enable the development of novel therapeutics that enhance patient lives by providing innovative and effective particle-based drug delivery solutions. The company envisions being a trusted partner for pharmaceutical and biotech companies, delivering superior value and driving the success of their clients.

Primary Area of Focus

The company focuses on particle-based drug delivery systems, including lipid nanoparticles (LNPs), polymeric nanoparticles (PNPs), and polymeric microspheres. These technologies are designed to optimize drug release rates, targeting abilities, bioavailability, and deliverability, aiming to achieve desired therapeutic effects while reducing adverse clinical outcomes.

Industry Significance

Phosphorex plays a pivotal role in the pharmaceutical and biotechnology sectors by providing specialized services that address the challenges associated with therapeutic agent delivery. Its expertise in nanomedicine and sustained-release formulations contributes to the advancement of drug delivery technologies, enhancing the efficacy and safety of various therapeutics.

Key Strategic Focus

Core Objectives

• Innovation in Drug Delivery: Develop and implement cutting-edge particle-based drug delivery systems to improve therapeutic outcomes.

• Comprehensive Support: Provide end-to-end services from proof-of-concept to clinical studies, ensuring seamless progression of client projects.

• Quality and Compliance: Maintain high standards of quality and adhere to regulatory requirements to ensure the safety and efficacy of developed formulations.

Specific Areas of Specialization

• Lipid Nanoparticles (LNPs): Specialize in LNPs for nucleic acid delivery, facilitating efficient cellular entry and endosome escape.

• Polymeric Nanoparticles (PNPs): Focus on PNPs for targeted delivery, enhancing the precision of therapeutic agent delivery.

• Polymeric Microspheres: Develop microspheres for sustained-release delivery, optimizing drug release profiles and improving patient compliance.

Key Technologies Utilized

• Formulation Development: Employ advanced techniques to design and optimize particle-based drug delivery systems.

• Process Development and Scale-Up: Utilize state-of-the-art facilities to scale up production processes, ensuring consistency and quality in larger batches.

• Analytical Services: Provide comprehensive analytical testing to characterize and validate formulations, ensuring they meet regulatory standards.

Primary Markets Targeted

Phosphorex primarily serves pharmaceutical and biotechnology companies involved in the development of novel therapeutics, including gene therapies, vaccines, and long-acting injectables. The company's services are crucial for organizations seeking to enhance the delivery and efficacy of their drug candidates.

Financials and Funding

Funding History

In August 2022, Phosphorex secured a majority recapitalization from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector. This investment was intended to expand the company's capabilities, including the establishment of current Good Manufacturing Practice (cGMP) manufacturing for lipid nanoparticles.

Recent Funding Rounds

• August 2022: Majority recapitalization by Ampersand Capital Partners.

• August 2024: Strategic investment by NOF CORPORATION, a global leader in lipid chemistry, to accelerate the establishment of Phosphorex's cGMP capabilities.

Notable Investors

• Ampersand Capital Partners: A private equity firm with over $3 billion in assets under management, focusing on growth-oriented investments in the healthcare sector.

• NOF CORPORATION: A Japanese company specializing in high-purity phospholipids and proprietary ionizable lipids for drug delivery applications.

Intended Utilization of Capital

The capital from these investments is being utilized to:

• Expand Facilities: Enhance laboratory and manufacturing spaces to support increased demand and scale-up capabilities.

• Establish cGMP Manufacturing: Develop current Good Manufacturing Practice facilities to produce lipid nanoparticles for clinical applications.

• Advance Technological Capabilities: Integrate advanced lipid technologies and analytical services to improve formulation development processes.

Pipeline Development

Key Pipeline Candidates

Phosphorex collaborates with clients to develop a range of drug delivery systems, including:

• Lipid Nanoparticles (LNPs): For the delivery of nucleic acids such as mRNA, siRNA, and DNA.

• Polymeric Nanoparticles (PNPs): For targeted delivery of small molecules and biologics.

• Polymeric Microspheres: For sustained-release formulations of various therapeutics.

Stages of Development

Phosphorex supports clients through all phases of development, from proof-of-concept to clinical studies, ensuring formulations are optimized for efficacy, stability, and safety.

Target Conditions

The company's drug delivery systems are designed for a variety of therapeutic areas, including:

• Gene Therapies: For the delivery of genetic material to target cells.

• Vaccines: For enhanced immune response through efficient antigen delivery.

• Oncology: For targeted delivery of chemotherapeutic agents to cancer cells.

• Infectious Diseases: For the delivery of antiviral agents.

Anticipated Milestones

Phosphorex aims to achieve the following milestones:

• Facility Expansion: Completion of expanded laboratory and manufacturing facilities.

• cGMP Manufacturing: Operationalization of cGMP manufacturing capabilities for lipid nanoparticles.

• Technological Integration: Full integration of advanced lipid technologies and analytical services into development processes.

Technological Platform and Innovation

Proprietary Technologies

• Ionizable Lipids: Utilized in lipid nanoparticles for efficient nucleic acid delivery.

• Formulation Development Platforms: Including microfluidics, jet mixing, T-mixing, and Tangential Flow Filtration for LNP fabrication.

Significant Scientific Methods

• Lipid Screening and Formulation Optimization: Collaborative efforts with NOF CORPORATION to provide ionizable lipid screening and formulation optimization services.

• Cryo-Electron Microscopy (Cryo-EM): Utilized for nanoparticle characterization, ensuring quality and integrity of formulations.

Leadership Team

Executive Team

• Jarlath Keating: Chief Executive Officer. Brings extensive experience in the pharmaceutical and biotechnology sectors, leading strategic initiatives and partnerships.

• David Tammaro: Chief Financial Officer. Oversees financial operations and strategic financial planning.

• Marc Kinnelly: Vice President, Quality Operations. Ensures adherence to quality standards and regulatory compliance.

Management Team

• Theresa Logan: Head of Laboratory Operations. Manages laboratory functions and ensures operational efficiency.

• Lisa Fitt: Director, Human Resources. Leads human resources strategies and initiatives.

• Nicholas Boylan, Ph.D.: Senior Director, Scientific Services. Oversees scientific research and development activities.

• Kim Yang: Director, Marketing. Leads marketing initiatives and brand management.